INTRODUCTION
Genome-wide sequencing has the capacity to link mutational signatures to specific mutagenic agents. Notable examples include C--to-T transitions in pyrimidine dimers induced by ultraviolet radiation (1) and C-to-A transversions induced by tobacco exposure (2) . A recent bioinformatics survey of tumor types occurring primarily in western populations identified at least 21 mutational signatures (3) . However, for most of these putative signatures, the exogenous or endogenous agent responsible has not been identified. This gap could, in principle, be filled through molecular epidemiologic studies linking exposure to agents with the mutational signature observed.
Another remarkable example of a mutational signature associated with a specific carcinogen is provided by data on upper tract urothelial carcinomas (UTUC) in Taiwan and the Balkans. These tumors harbor a high content of A-to-T transversions, affecting adenines genome-wide within a set of specific trinucleotide sequences (4, 5) . This mutational signature has been linked to aristolochic acid (AA), a nitrophenanthrene carboxylic acid found in Aristolochia species (6) used worldwide in the practice of traditional herbal medicine (7) .
Following metabolic activation, AA forms AL-DNA adducts that serve as specific biomarkers of exposure to AA (8) . Remarkably, AL-DNA adducts can be detected in normal human tissues decades after exposure to AA (9) (10) (11) . These adducts were also found in the normal kidney tissues of individuals in Taiwan (12) , a country with one of the highest rates of UTUC in the world. In Taiwan, prescription data reveal that one in three residents had ingested herbs containing AA (13) .
In rodents exposed to AA, pro-mutagenic AL-DNA adducts are found in kidney, liver, forestomach, and bladder (14, 15) . Thus, we hypothesized that AA contributes to cancers of the corresponding tissues in humans. In fact, signatures resembling the AA-mutational signature have been reported to occur in bladder cancer (BC) (16) , a small fraction of hepatocellular carcinomas (HCC) in China (5, 17) , Japan (18) and the US (18) , and in intrahepatic cholangiocarcinomas (IHCC) from China (19) , and in clear cell renal cell carcinomas (ccRCC) in China (20) , Romania (21) and the endemic region of Croatia (22) . AL-DNA adducts have also been detected in kidney DNA from Romanian ccRCC patients (23) .
Thus AA could be involved in the initiation and/or progression of tumors in these tissues. However, for HCC, IHCC and ccRCC, integrated epidemiological and molecular evidence linking AA exposure to the incidence of these cancers has not been available.
In the present study, we bridge this gap by applying both epidemiological and molecular approaches to the Taiwanese population, where a high fraction of the population has been exposed to AA (13) . Specifically, we provide strong evidence linking AA exposure to ccRCC pathogenesis in this population by demonstrating an association between AA exposure and ccRCC incidence, by measuring AL-DNA adducts in the renal cortex of ccRCC patients, and by detection of the AA-mutational signature in ccRCC tumors from patients previously exposed to AA.
MATERIALS AND METHODS
The research protocols were reviewed and approved by the Institutional Review Boards of Stony Brook University and the National Taiwan University.
Prescription database analysis
The Taiwan National Health Insurance (NHI) covers >96% of Taiwanese residents and reimburses cost of prescriptions, including Chinese herbal products. RCC cases were identified from the NHI catastrophic illness registry using ICD-9 code 189.0. A total of 5,709 RCC patients and 22,836 controls were enrolled from 1999 to 2008. The index date for each case was the date of diagnosis with RCC, and we defined the index date of control subjects as the date of RCC diagnosis of their corresponding cases. RCC patients with other cancers (ICD-9 140-208) or kidney transplant (V42.0) were excluded from this study. Each case was paired with 4 controls randomly selected from the insured population, which were matched by sex, age, income and urbanization.
The Taiwan NHI regularly reimbursed enrollees for the cost of prescribed Chinese herbs medicines containing AA, which were prescribed extensively before the ban in 2003. During our investigation period, the detailed herbal prescriptions, including regimen, dosage, duration and prescription date were uploaded to NHI for obtaining payment. All prescribed herbal medications were covered by the Taiwan NHI and required a doctor's prescription. Usage of AAcontaining herbs in each case and control was determined and calculated from Mass spectrometric determination of AL-DNA adducts AL-DNA adduct concentrations in five micrograms of kidney DNA were determined by ultraperformance liquid chromatography-electrospray ionization/multistage scan mass spectrometry as previously described (25, 26) .
RESULTS

Evidence of exposure to aristolochic acid-containing herbs in patients with ccRCC in Taiwan
In Taiwan, 39% of the population received prescriptions for Aristolochiacontaining remedies during the years 1997-2003 (13 Aristolactam DNA-adducts levels in renal tissues of ccRCC patients Molecular evidence that Taiwanese ccRCC patients were exposed to AA was obtained using a quantitative mass-spectrometric method to measure dA-AL-I-DNA adduct levels. Genomic DNA was isolated from the non-neoplastic renal cortical tissue of 51 Taiwanese RCC patients (Supplementary Table 1 ). AAexposure induces dA and dG adducts derived from AAI and AAII (Fig. 1) ; the dA-AL-I adduct is resistant to DNA repair and can be detected in renal cortex DNA decades after exposure. We detected AL-DNA adducts in 39 of 51 (76%) patients tested ( indicate that at least 76% of the patients in our cohort consumed AA-containing herbs. Importantly, in these individuals, dA-AL adducts were found within the same tissue that generated the tumor.
Whole exome sequencing of ccRCCs
We hypothesized that if AA exposure directly contributed to ccRCC tumorigenesis, then the tumor genome should harbor the characteristic AA mutational signature. To test this hypothesis, we performed whole exome sequencing on tumor and non-tumor DNA pairs from 5 men and 5 women who had been exposed to AA. Each patients selected had significant amounts of AL-DNA adducts in their renal DNA (Fig. 1) . From the sequencing data, we identified (range, 26 to 78). Tumor purity in ccRCC samples is generally low, as reported in
The Cancer Genome Atlas (TCGA) exome sequencing study of 417 ccRCCs (median 54% ± 14%) (27) . Due to the high coverage of our whole exome sequencing, this did not pose a limitation to the identification of somatic mutations. The average high quality coverage of each base in the targeted region was 96-fold; 93% of the targeted region contained at least 10 reads.
Furthermore, we observed no correlation between neoplastic cell content and the total number of somatic mutations identified for each tumor ( Table 2) .
Identification of somatic mutations
We used stringent criteria to identify a total of 1,204 somatic mutations with a median of 87 per tumor (range, 18 to 334) ( Fig Nonsynonymous mutations were found in 853 genes, including several genes found to be significantly mutated in prior studies of ccRCC. VHL was the most frequently mutated driver gene (seven of 10 tumors) in our AA-exposed ccRCCs ( Table 2 ). The second most frequent was PBRM1, with inactivating mutations in two out of ten tumors. VHL and PBRM1 were also the two most frequent significantly mutated driver genes in the TCGA ccRCC study and occurred at a similar mutation frequency as our cohort (53% VHL, 34% PBRM1) (27) . We also observed mutations in other known ccRCC driver genes, including the tumor suppressors SETD2, BAP1, GNB2L1, and EPAS1, as well as an oncogenic mutation in PIK3CA (Supplementary Table 2 Fig. 1 ). These data suggest that AA-exposed and TCGA individuals share common ccRCC driver genes.
Mutational patterns of single base substitutions in ccRCC
We next asked if the AA-exposed ccRCC tumors harbored the main feature of the AA mutational signature, an elevated frequency of A-to-T transversions. Indeed the fraction of A-to-T transversion mutations in the ten AAexposed ccRCC was significantly higher (33±23%, mean±s.d.) than in the TCGA ccRCCs (10.7±4.4%) (P<0.0001, two-tailed t-test) (Fig. 3A) . However, we observed a wide distribution of A-to-T transversion fraction in our ten AAexposed ccRCCs (range 7-69%) compared to TCGA ccRCCs (range 0-26%).
We took advantage of the TCGA ccRCC cohort data to define a stringent criterion for the expected fraction of A-to-T transversions. Two standard deviations above the TCGA ccRCC cohort average was set as a threshold and tumors with A-to-T transversion fractions above this value (>20%) were designated as having elevated A-to-T. In six tumors of our AA-exposed cohort, the A-to-T fraction exceeded 20% of the SBSs (Fig. 3B) . Note that 2.4% of the TCGA ccRCCs (10 of 417 tumors) has an A-to-T fraction greater than 20%.
However, without the complementary AL-DNA adduct analysis to implicate AA, the elevated A-to-T fraction could have been due to other factors, including compounds whose metabolites lead to A-to-T mutations (29) .
We compared the SBS mutational spectra of the following three ccRCC cohorts: (1) AA-exposed individuals with high A-to-T fractions (n=6), (2) AAexposed individuals with low A-to-T fractions (n=4), and (3) TCGA individuals (Fig. 3C) . The difference between the high A-to-T set and the TCGA dataset was primarily in the excess of A-to-T transversion mutations among the SBSs. After the A-to-T class is removed, the relative ranking of the other classes of SBSs is similar to that seen in the TCGA samples. This pattern in AAassociated ccRCC -an excess of A-to-T transversions -is reminiscent of that observed in AA-associated UTUC.
Aristolochic acid mutational signature
We examined 488 A-to-T mutations compiled from the six ccRCC cases with an excess fraction of A-to-T transversions for key features of the AAmutational signature observed in AA-associated UTUC. dA-AL adducts are repaired efficiently by transcription-coupled DNA repair but only poorly by global genome repair (30) . Indeed the deoxyadenosine residue mutated in A-to-T transversions was found primarily on the non-transcribed strand in these ccRCCs (Fig. 4A) . In contrast, we observed no strand preference for the deoxyadenosine residue among A-to-T transversions in the TCGA dataset (Fig. 4A) . The A>T strand biases in AA-associated ccRCCs and AA-associated UTUCs were 2.1-fold and 2.6-fold, respectively(4).
The sequence context of A-to-T mutations was probed by tabulating the bases neighboring the mutated deoxyadenines. Figure 4B -27 , two-sided Chi-square). In Taiwanese AA-associated UTUCs, the CpApG trinucleotide was also found in similar proportion, 33% (3365/10326) in AA-associated UTUCs compared to 10% (503/5250) in controls (4).
Exon splice acceptor sites almost always occur at ApG sequences and are most frequently found in a CpApG context. Consistent with an increased Ato-T preference for the CpApG context, the frequency of mutations in the splice acceptor was elevated in ccRCC compared to TCGA (2.8% versus 1.0% of substitutions, respectively) (Fig. 4C) . The ratio of the number of mutations at splice acceptor to splice donor sites was 3.4-fold (24/7) in the Taiwanese ccRCCs. In contrast, there was no splice site mutation preference observed among ccRCCs in the TCGA dataset (1.1-fold, 269/251; P=0.0021 two-sided Fisher's Exact Test). The excess of splice acceptor mutations was less than that observed in AA-associated UTUC exome sequences (6.9-fold)(4). In summary, all significant features of the AA-mutational signature reported for AA-associated UTUCs were found in this set of Taiwanese ccRCCs and were highly statistically significant. We made no attempt to match our cohort to the TCGA with respect to known ccRCC risk factors such as smoking history and BMI. But as the TCGA set completely lacks the AA-mutational signature we can confidently conclude that these known risk factors, represented abundantly in the TCGA set, do not produce the mutational signature we are attributing to AA in ccRCC. In other studies, DNA was obtained from RCC cases in England, Russia, the Czech Republic, and Romania (21) and also from the endemic region of Croatia (22) . The mutation spectrum in RCCs from England, Russia, and the Czech Republic resembled that seen in the TCGA RCC study (drawn from an American population); however, the AA-mutational signature predominated a majority of the Romanian RCCs (12/14) and 4/8 Croatian RCCs. Although Romania has long been known to harbor regions of endemic nephropathy, the RCC patients whose tumors were sequenced apparently did not reside in the endemic areas. However, the therapeutic use of Aristolochia herbs is known to occur in Romania (33) and a follow-up study did establish the presence of AL-DNA adducts in Romanian RCC patients (23) .
The fraction of individuals with AL-DNA adducts is similar among Taiwanese patients with UTUC and RCC (12) . Although our case-control study showed that patients who took a cumulative dosage of more than 250 mg of AA had an increased RCC risk (crude OR = 1.4); a similar study reported a higher risk of urothelial carcinoma (bladder cancer and/or UTUC) among Taiwanese ingesting similar amounts of AA (crude OR = 1.9) (24) . Also, the number of A-to-T transversions per exome are higher in UTUC with the AA-mutational signature than AA-related RCC (median = 188 per exome in UTUC and 46 per exome in RCC). While these results indicate that renal tissue is sensitive to the carcinogenic effects of AA, they also suggest that the urothelium may be more sensitive to these effects. An alternative explanation is that the nephrotoxic effects of AA dominate renal tumorigenesis and thus AA-induced RCC develops only in the minority of people sensitive to the nephrotoxic effects of AA.
Regardless of the precise mechanism, the present study offers compelling evidence implicating AA in a significant fraction of the RCC arising in Taiwan 
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